Compare Cronos Group Inc (CRON) vs Nutanix Inc (NTNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Nutanix Inc — how do they compare? Cronos Group Inc trades at $2.74 (market cap $1.02B), while Nutanix Inc trades at $55.65 (market cap $14.99B). The key difference: Nutanix Inc is far larger — about 14.7× Cronos Group Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, Nutanix Inc nearer its low. Which is the better fit depends on your goals.
| CRON | NTNX | |
|---|---|---|
Market Cap | $1.02B | $14.99B |
Sector | Health | Technology |
52-Week High | $3.27 | $81.12 |
52-Week Low | $1.95 | $34.41 |
Enterprise Value | $203.29M | $14.51B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $2.75, showing no change recently. The stock has a mixed technical outlook with a neutral overall signal but bullish moving averages. Fundamentally, revenue grew to $146.59M in 2025, but net income was negative at -$9.45M. Recent news highlights strong Q1 2026 revenue growth of 40% and expansion of its Spinach brand portfolio, though the company faces intense cannabis sector competition.
Outlook is cautious with growth potential from international expansion and market share gains, but profitability remains a challenge. Risks include regulatory uncertainty and competitive pressures. Analyst sentiment is mixed with 60% hold ratings. The stock presents a speculative opportunity for investors betting on continued top-line growth and eventual margin improvement.
Nutanix (NTNX) trades at $55.22, up 0.78% on the day, reflecting positive momentum. The stock exhibits a bullish technical trend with strong moving average support and is trading near key resistance at $56. Fundamentally, the company demonstrates robust revenue growth, with Q3 2026 results beating expectations, and maintains a high gross profit margin of 87.09%. Recent news highlights strategic partnerships and NVIDIA certification for its AI infrastructure solutions.
The outlook for NTNX is positive, driven by consistent earnings beats, strong analyst consensus (62.5% Buy ratings), and a $57.80 price target suggesting modest upside. Key risks include its high valuation multiples (P/E of 58.39) and execution challenges in a competitive cloud software market. Investor sentiment is buoyed by its positioning in hybrid multicloud and AI growth areas.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
